Automate Your Wheel Strategy on INMB
With Tiblio's Option Bot, you can configure your own wheel strategy including INMB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol INMB
- Rev/Share 0.0022
- Book/Share 1.319
- PB 1.7513
- Debt/Equity 0.0117
- CurrentRatio 2.6441
- ROIC -1.0487
- MktCap 61412043.0
- FreeCF/Share -1.454
- PFCF -1.8775
- PE -1.2738
- Debt/Assets 0.0092
- DivYield 0
- ROE -1.1866
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | INMB | BTIG Research | Buy | Neutral | -- | -- | July 1, 2025 |
| Downgrade | INMB | Scotiabank | Sector Outperform | Sector Underperform | -- | $0.6 | July 1, 2025 |
| Initiation | INMB | Rodman & Renshaw | -- | Buy | -- | $23 | Jan. 28, 2025 |
| Initiation | INMB | Alliance Global Partners | -- | Buy | -- | $20 | Oct. 21, 2024 |
| Initiation | INMB | Raymond James | -- | Outperform | -- | $18 | Sept. 27, 2024 |
| Initiation | INMB | Scotiabank | -- | Sector Outperform | -- | $22 | Aug. 22, 2024 |
News
'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday
Published: July 04, 2025 by: Benzinga
Sentiment: Negative
Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge.
Read More
INmune Bio shares tumble as Alzheimer's drug falls short in mid-stage trial
Published: June 30, 2025 by: Proactive Investors
Sentiment: Negative
INmune Bio Inc (NASDAQ:INMB) shares plummeted almost 60% following disappointing results from a Phase 2 clinical trial of its experimental Alzheimer's drug, XPro. The drug failed to meet the primary cognitive endpoint in the overall intent-to-treat population, meaning it did not significantly improve cognitive function over six months compared to placebo in early Alzheimer's patients.
Read More
INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Published: June 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Boca Raton, Florida, June 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has entered into securities purchase agreements with two healthcare focused institutional investors for the purchase and sale of 3,000,000 shares of its common stock in a registered direct offering (the "Offering") at a purchase price of $6.30 per share, priced at-the-market under Nasdaq rules.
Read More
INmune Bio: Imminent Phase 2 Alzheimer's Readout Of Unique Asset Presents Interesting Speculative Opportunity
Published: June 16, 2025 by: Seeking Alpha
Sentiment: Positive
INmune Bio offers a high-risk, high-reward opportunity ahead of its Phase 2 Alzheimer's readout. Lead asset XPro1595's mechanism of selectively targeting soluble TNF (sTNF) has strong preclinical, mechanistic, and limited but encouraging Phase 1b data. If XPro1595 delivers positive results, it could validate a new approach in Alzheimer's and other inflammatory diseases, but the investment remains speculative due to clinical and market risks.
Read More
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial (the “CaRe PC” trial) for men with metastatic castration-resistant prostate cancer (mCRPC). The Company is pleased to announce completion of the third and highest dose cohort of the Phase I portion of the trial allowing opening of the Phase II high dose cohort.
Read More
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
Boca Raton, Florida, Feb. 10, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”) , a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, announced today, following a Type C meeting with the U.S. Food and Drug Administration (FDA), its intent to submit a BLA in the US and Marketing Authorization Application (MAA) in the UK and EU supported by data from the MissionEB clinical trial investigating CORDStrom as a disease-modifying therapy for treating RDEB in pediatric patients.
Read More
About INmune Bio, Inc. (INMB)
- IPO Date 2019-02-04
- Website https://www.inmunebio.com
- Industry Biotechnology
- CEO Raymond Joseph Tesi
- Employees 13